Provided by Tiger Fintech (Singapore) Pte. Ltd.

Astria Therapeutics Inc

5.57
+0.13002.39%
Post-market: 5.570.00000.00%19:30 EDT
Volume:1.35M
Turnover:7.54M
Market Cap:314.34M
PE:-2.97
High:5.64
Open:5.44
Low:5.41
Close:5.44
Loading ...

Astria Therapeutics Reports Q1 2025 Financial Results: Net Cash Used in Operations Increases to $34 Million

Reuters
·
14 May

Astria Therapeutics Q1 Operating Expenses USD 36.995 Million

THOMSON REUTERS
·
14 May

Press Release: Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Dow Jones
·
14 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
08 May

Astria Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview

Reuters
·
05 May

Astria Therapeutics Announces New Stock Option Grants Under 2022 Inducement Plan for New Employees

Reuters
·
03 May

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
03 May

Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology

Business Wire
·
01 May

Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference

Business Wire
·
30 Apr

Astria Therapeutics Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
29 Apr

Top Premarket Decliners

MT Newswires Live
·
21 Apr

Astria Therapeutics Q4 EPS $(0.44) Beats $(0.45) Estimate

Benzinga
·
11 Mar

Press Release: Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Dow Jones
·
11 Mar

TD Cowen Sticks to Its Buy Rating for Astria Therapeutics (ATXS)

TIPRANKS
·
10 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
05 Mar

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Mar

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire
·
05 Mar

Astria Therapeutics Price Target Maintained With a $26.00/Share by Citizens Capital Markets

Dow Jones
·
03 Mar

TD Cowen Remains a Buy on Astria Therapeutics (ATXS)

TIPRANKS
·
02 Mar

Astria Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Feb